← Leaderboards
Sheri Denet Klas
Siteone Therapeutics, Inc.
$1,802,944
Attributed
$1,964,810
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–22$2M$1.5M$1M$500K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$1,964,810 · 2
By mechanism
R44$1,641,077 · 1
R43$323,733 · 1
Top collaborators
- John Cureton Hunter1 shared
Most similar at Siteone Therapeutics, Inc.
Same institution · by research overlap
- John Vincent Mulcahy$6,301,912
- John Cureton Hunter$6,388,430
- Anton Delwig$2,325,019
- Debra Odink$3,260,885
- George Miljanich$601,209
Others in their field
Other Emerging Leaders on “Side Effect”
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Jacob D Estes · Oregon Health & Science University$9,581,486
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Gary Fanger · Rise Therapeutics, Llc$8,225,136
- Katherine Teresa Mills · Tulane University Of Louisiana$7,657,098
- Warren David Lo · Virginia Polytechnic Inst And St Univ$7,249,509
Research focus
Side EffectVoltagePharmaceutical PreparationsSeriesSodium ChannelToxicologyFormulationMedicalReflex ActionSafety StudySmall Business Innovation Research GrantSmall Molecule InhibitorSubcutaneousEfficacy StudyExhibitsChronicInhalationIn VivoPharmacotherapyProgramsRouteSafetyDoseDry Eye Syndromes
Grant awards (3)
Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain$559,962
R44 · FY2022 · EY · contact PI
Development of a Selective Inhibitor of NaV1.7 for the Treatment of Ocular Pain$1,081,115
R44 · FY2021 · EY · contact PI
Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough$323,733
R43 · FY2019 · HL